382 related articles for article (PubMed ID: 23661802)
1. Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage.
Waaijenborg S; Hahné SJ; Mollema L; Smits GP; Berbers GA; van der Klis FR; de Melker HE; Wallinga J
J Infect Dis; 2013 Jul; 208(1):10-6. PubMed ID: 23661802
[TBL] [Abstract][Full Text] [Related]
2. [Prevalence of maternal measles, rubella, mumps and varicella antibodies in the first six months of life].
Devecioğlu E; Gökçay G; Boran P; Eren T; Yılmaz G; Badur S
Mikrobiyol Bul; 2018 Jul; 52(3):324-327. PubMed ID: 30156519
[TBL] [Abstract][Full Text] [Related]
3. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
[TBL] [Abstract][Full Text] [Related]
4. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
Carryn S; Feyssaguet M; Povey M; Di Paolo E
Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
[TBL] [Abstract][Full Text] [Related]
5. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
[TBL] [Abstract][Full Text] [Related]
7. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
8. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
Nolan T; McIntyre P; Roberton D; Descamps D
Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
[TBL] [Abstract][Full Text] [Related]
9. The impact of maternal measles-rubella immunization on the 12-month-old infant's immune response to measles-mumps-rubella vaccine immunogenicity.
Saffar MJ; Ajami A; Khalilian AR; Saffar H
Eur J Clin Microbiol Infect Dis; 2009 Jul; 28(7):845-7. PubMed ID: 19229565
[TBL] [Abstract][Full Text] [Related]
10. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants.
Yerkovich ST; Rowe J; Richmond P; Suriyaarachchi D; Heaton T; Hollams E; Ladyman C; Serralha M; Sadowska A; Loh R; Wesselingh SL; Sly PD; Holt PG
Vaccine; 2007 Feb; 25(10):1764-70. PubMed ID: 17224218
[TBL] [Abstract][Full Text] [Related]
12. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
Shinefield HR; Black S; Kuter BJ
J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
[TBL] [Abstract][Full Text] [Related]
14. Duration of immunity to measles, rubella and mumps during the first year of life.
Cilleruelo MJ; Fernández-García A; Villaverde S; Echevarría J; Marín MÁ; Sanz JC; López A; Royuela A; Antoran BR; de Ory F
Vaccine; 2019 Jul; 37(30):4164-4171. PubMed ID: 31151799
[TBL] [Abstract][Full Text] [Related]
15. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
[TBL] [Abstract][Full Text] [Related]
16. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.
Chaiwarith R; Praparattanapan J; Nuket K; Kotarathitithum W; Supparatpinyo K
BMC Infect Dis; 2016 Apr; 16():190. PubMed ID: 27138005
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
Sultana R; Rahman MM; Hassan Z; Hassan MS
Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
[TBL] [Abstract][Full Text] [Related]
18. Early disappearance of maternal anti-measles, mumps, rubella, and varicella antibodies in Indian infants.
Malshe N; Palkar S; Kulkarni R; Lalwani S; Mishra AC; Arankalle V
Vaccine; 2019 Mar; 37(11):1443-1448. PubMed ID: 30765170
[TBL] [Abstract][Full Text] [Related]
19. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
Leung JH; Hirai HW; Tsoi KK
Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
